Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corbus Pharma (CRBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 395,893
  • Shares Outstanding, K 57,210
  • Annual Sales, $ 2,440 K
  • Annual Income, $ -32,420 K
  • 36-Month Beta 2.17
  • Price/Sales 158.02
  • Price/Cash Flow N/A
  • Price/Book 6.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.22
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.80 +44.17%
on 09/17/18
8.57 -19.25%
on 10/02/18
+1.97 (+39.80%)
since 09/14/18
3-Month
4.50 +53.78%
on 08/08/18
8.57 -19.25%
on 10/02/18
+1.27 (+22.48%)
since 07/13/18
52-Week
4.50 +53.78%
on 08/08/18
9.95 -30.49%
on 01/30/18
+0.12 (+1.76%)
since 10/13/17

Most Recent Stories

More News
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.

CRBP : 6.92 (+2.67%)
PCRX : 45.32 (+2.67%)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October

- Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1at 2:55 PM ET -

CRBP : 6.92 (+2.67%)
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

CRBP : 6.92 (+2.67%)
Today's Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Aytu Bioscience

NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Biotech stocks Corbus Pharmaceuticals and Aytu BiosScience were both roaring on Thursday. Shares of Corbus exploded on the news that it has expanded its...

CRBP : 6.92 (+2.67%)
AYTUD : 4.1000 (+3.80%)
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from...

CRBP : 6.92 (+2.67%)
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union

- Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin

CRBP : 6.92 (+2.67%)
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented

CRBP : 6.92 (+2.67%)
Vertex Completes Enrollment in Triple Combination Studies

Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

CRBP : 6.92 (+2.67%)
VRTX : 177.65 (-2.02%)
ABBV : 89.18 (-1.67%)
GLPG : 97.08 (-2.52%)
Vertex Inks Reimbursement Agreement for Orkambi in Australia

Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

CRBP : 6.92 (+2.67%)
VRTX : 177.65 (-2.02%)
ABBV : 89.18 (-1.67%)
GLPG : 97.08 (-2.52%)
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics...

CRBP : 6.92 (+2.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRBP with:

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

2nd Resistance Point 7.47
1st Resistance Point 7.19
Last Price 6.92
1st Support Level 6.55
2nd Support Level 6.18

See More

52-Week High 9.95
Fibonacci 61.8% 7.87
Fibonacci 50% 7.23
Last Price 6.92
Fibonacci 38.2% 6.58
52-Week Low 4.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar